5-HT transporter Inhibitors
2 drugsAbout 5-HT transporter
The serotonin transporter (5-HT transporter or SERT) regulates serotonin levels in the synaptic cleft by mediating reuptake into the presynaptic neuron. This controls serotonergic neurotransmission, impacting mood, behavior, and physiological functions.
The 5-HT transporter is a drug target for CNS disorders, but there is currently no genetic evidence available linking it to specific diseases.
Two FDA-approved drugs, TRINTELLIX (Takeda) and PAROXETINE (PRINSTON INC), target the 5-HT transporter. Both drugs are small molecules and are used in CNS therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Solid Tumor with only 1 trials.
- phase3 represents biological uncertainty with 29% completion.
Top 5-HT transporter Drugs
Takeda and PRINSTON INC are the companies with approved drugs targeting the 5-HT transporter.
The market is not highly concentrated, suggesting opportunities for new entrants with differentiated therapies.
5-HT transporter Drug Modality Landscape
Modalities
Routes of Administration
5-HT transporter is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing drugs.
5-HT transporter Clinical Trials 121 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 32 | 29 | 1 | 2 | 97% |
| Phase 2 | 16 | 11 | 2 | 3 | 85% |
| Phase 3 | 33 | 24 | 9 | 0 | 73% |
| Phase 4 | 40 | 29 | 8 | 3 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-HT transporter Drug Approval Timeline (2013 - 2014)
The first drug, TRINTELLIX, was approved in 2013, and the most recent, PAROXETINE, in 2014.
The short approval span suggests potential saturation or challenges in developing new 5-HT transporter modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 70 clinical trials targeting 5-HT transporter.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities